Evidence map›Paper›PMID 32643448›Full record

ArticleDrug development and industrial pharmacy2020

Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.

Quyuan Tao, Jiaxin Du, Xiantao Li, Jingyan Zeng, Bo Tan, Jianhua Xu, Wenjia Lin, Xin-Lin Chen

Open access · greenAbstract read
In one paragraph

Article in Drug development and industrial pharmacy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 2 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 212 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Psoriasis intervention by Huai'er (): unveiling novel targetsnetwork pharmacology.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Effect and mechanism of Sanqi () in treating periodontitis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Quyuan TaoSchool of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jiaxin DuSchool of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiantao LiSchool of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jingyan ZengThe First Clinical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Bo TanSchool of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jianhua XuMedical Laboratory Center, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.
Wenjia LinSchool of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xin-Lin ChenSchool of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.ORCID https://orcid.org/0000-0002-2650-8051
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHuashi Baidu formula (HSBDF) was developed to treat the patients with severe COVID-19 in China. The purpose of this study was to explore its active compounds and demonstrate its mechanisms against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through network pharmacology and molecular docking.

methodsAll the components of HSBDF were retrieved from the pharmacology database of TCM system. The genes corresponding to the targets were retrieved using UniProt and GeneCards database. The herb-compound-target network was constructed by Cytoscape. The target protein-protein interaction network was built using STRING database. The core targets of HSBDF were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The main active compounds of HSBDF were docked with SARS-CoV-2 and angiotensin converting enzyme II (ACE2).

resultsCompound-target network mainly contained 178 compounds and 272 corresponding targets. Key targets contained MAPK3, MAPK8, TP53, CASP3, IL6, TNF, MAPK1, CCL2, PTGS2, etc. There were 522 GO items in GO enrichment analysis (

conclusionBaicalein and quercetin in HSBDF may regulate multiple signaling pathways through ACE2, which might play a therapeutic role on COVID-19.

Indexed as

Angiotensin-Converting Enzyme 2BetacoronavirusChinaCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDatabases, FactualDrugs, Chinese HerbalGene OntologyGenes, ViralGene TargetingHumansMedicine, Chinese TraditionalMolecular Docking SimulationPandemicsPeptidyl-Dipeptidase AACE2 protein, humanAngiotensin-Converting Enzyme 2Drugs, Chinese Herbalhuashi baiduPeptidyl-Dipeptidase AcoronavirusHuashi Baidu formulamolecular dockingnetwork pharmacologySARS-CoV-2

Identifiers

PMID32643448
PMCPMC7441778
OpenAlexW3041403959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.